

- **Name:** Dae Young ZANG
  - **Current Position & Affiliation:** Professor, Hallym University
  - **Country:** Korea
- 

**• Educational Background:**

M.D., Ph.D., Internal Medicine, Hallym University  
Postdoctoral fellowship, Clinical Research Division, Fred Hutchinson Cancer Research Center, U.S.A.

**• Professional Experience:**

Director of Hallym Institute for Clinical Medicine, Hallym University Medical Center  
Visiting Professor, Weill Cornell Cancer Center, New York Presbyterian Hospital, Weill Cornell Medical College, New York, U.S.A.  
Visiting Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, U.S.A.  
Research Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center, U.S.A.  
Clinical and Research Fellowship, Division of Hematology and Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine

**• Professional Organizations:**

Chairman, Stomach Cancer Committee of Korean Cancer Study Group (KCSG)  
Chairman, Health Insurance Policy Committee, Korean Cancer Association (KCA)  
Chairman, Ethics Committee, Korean Society of Medical Oncology (KSMO)  
Chairman, Education and Training Committee, Korean Society of Hematology (KSH)  
Member, American Society of Clinical Oncology (ASCO)  
Member, European Society of Medical Oncology (ESMO)

**• Main Scientific Publications:**

1. Tivantinib Inhibits the VEGF Signaling Pathway and Induces Apoptosis in Gastric Cancer Cells With c-MET or VEGFA Amplification, Invest New Drugs. 2020
2. Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling, OncoTargets and Therapy. 2020
3. The effects of crizotinib in a transgenic Drosophila model expressing the human TPM4-ALK fusion gene or TPM4, Biol Open. 2019
4. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11, Gastric Cancer. 2018
5. Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer, Cancer Res Treat. 2018

6. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia, Clin Cancer Res. 2017
7. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia, J Clin Oncol. 2017
6. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer, Gastric Cancer. 2016
7. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer, J Clin Oncol. 2015
8. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS), Ann Oncol. 2015
9. A Multi-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer, J Cancer. 2015
10. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia, Blood. 2015
11. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer, Cancer Chemother Pharmacol. 2015
12. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis, Ann Oncol. 2013
13. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer, Cancer Chemother Pharmacol. 2013
14. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia, Blood 2011
15. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer, Ann Oncol 2009
16. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on vitro hemopoiesis, Blood 2001